Indian drugmaker Strides Arcolab is considering the sale of its Australian branded-generics unit, Ascent

RELATED ARTICLES M&M gears up to launch XUV500 in Italy, Australia, Chile Strides Arcolab Jan-Mar net profit zooms to Rs 642 cr

Pharmahealth, a national daily reported on Monday.

US investment bank Jefferies and Co is advising Strides Arcolab on a divestment plan that may also include other businesses such as softgel and anti-retro viral drug manufacturing, as the drugmaker wants to focus on specialty injectables, the report said, citing sources.

Strides Arcolab declined to comment.

Ascent Pharmahealth is one of the largest branded generic drugmakers in Australia, with 13% market share. It also has a significant presence in Singapore, Thailand and Vietnam.

The business had sales of $140 million in 2010, the report said.